Oura Health filed for a United States initial public offering this week, converting a $2.55 billion private valuation—set in a $200 million Series D last year—into a test of whether wearable hardware can sustain public-market scrutiny. The Finnish company, known for titanium rings that track sleep and recovery metrics, has grown revenue three-fold since 2021 while losses widened in parallel. The filing arrives as athletes from the NBA to European football increasingly wear Oura rings during training cycles, a distribution fact that matters more to allocators than consumer PR.
Revenue climbed to approximately $500 million in trailing twelve months, driven by a combination of $299–$449 hardware sales and $5.99 monthly subscription fees that unlock granular health analytics. The company ships roughly 1.5 million rings annually, with North America accounting for 62% of unit volume. Losses expanded to an estimated $80 million over the same period, reflecting engineering spend on a fourth-generation ring launching mid-2025 and a sales force targeting corporate wellness buyers. Oura's margin structure—68% gross on hardware, 91% on subscriptions—suggests the unit economics improve as the subscriber base ages, but the company has not yet published cohort retention beyond year one.
The IPO timing reflects two pressures. First, venture debt taken in 2023 matures in early 2026, creating a refinancing need that public markets can satisfy more cleanly than another private round. Second, competitive encirclement: Samsung launched a smart ring in August 2024, and Apple has filed patents for ring-form sensors, compressing Oura's window to establish standalone brand value before platform players enter. The filing does not name underwriters or price range, but comparable wearable companies—Fitbit at IPO, Whoop in private markets—suggest Oura will target a $3–3.5 billion public valuation, an approximately 25% step-up from private marks.
What allocators should track: the percentage of revenue derived from subscriptions versus hardware in the S-1 details, expected within 30 days. If subscriptions exceed 40% of total revenue, the company can credibly argue it is a data business with hardware distribution, a narrative that commands SaaS-style multiples. If hardware still dominates, Oura is a consumer-electronics company with churn risk. Second, watch enterprise partnership announcements in Q2 2025. Oura has pilot programs with 12 professional sports teams and 200+ corporate wellness accounts; converting those pilots into multi-year contracts before roadshow would validate the B2B expansion thesis. Third, monitor Samsung's ring shipment volume, which analysts estimate at 400,000 units in the first six months—enough to matter, not enough to kill.
The filing's deeper signal is not Oura's readiness but the public market's willingness to pay for biometric infrastructure before interoperability standards exist. Luxury hospitality groups have begun offering Oura rings as in-room amenities at properties where sleep optimization is a service layer; six hotel brands now include rings in wellness suites. That adoption pattern—hardware as amenity, data as differentiator—suggests Oura's value accrues not to the ring itself but to the behavioral data it generates, a fact the prospectus will need to quantify in user lifetime value to justify the valuation being tested.